Testosterone Cypionate for Male Hypogonadism

What Is Male Hypogonadism and Who Qualifies for Treatment?

Male hypogonadism is defined by the Endocrine Society as a total serum testosterone below 300 ng/dL confirmed on two separate morning blood draws, combined with at least one clinically consistent symptom such as reduced libido, fatigue, depressed mood, loss of muscle mass, or erectile dysfunction. The CDC harmonized reference cutoff sits slightly lower at 264 ng/dL, but most prescribing guidelines use 300 ng/dL as the actionable threshold. Roughly 2, 4 million American men carry a formal diagnosis, and prevalence rises sharply after age 45.

Primary hypogonadism originates in the testes (elevated LH, elevated FSH, low T). Hypogonadotropic hypogonadism originates in the hypothalamic-pituitary axis (low or inappropriately normal LH and FSH with low T). Both forms qualify for testosterone replacement therapy under the 2018 Endocrine Society Clinical Practice Guideline, provided the diagnosis is biochemically confirmed and symptoms are present.

Age-related decline in testosterone, sometimes called "late-onset hypogonadism," requires the same two-draw confirmation process. The Endocrine Society guideline advises against treating men whose total testosterone falls in the normal range (above 400 ng/dL) even when symptoms overlap with hypogonadism, because the evidence for benefit is weak in that population.

Secondary causes must be ruled out first. Obesity, type 2 diabetes, obstructive sleep apnea, opioid use, and chronic illness all suppress testosterone. A 10% weight reduction in obese men can raise total testosterone by 60 to 80 ng/dL without pharmacotherapy, as shown in a 2019 meta-analysis in the European Journal of Endocrinology (N=1,573).

FDA Approval and Regulatory History

Testosterone cypionate carries full FDA approval for the treatment of male hypogonadism, both primary and hypogonadotropic. The FDA-approved prescribing label lists hypogonadism due to deficiency or absence of endogenous testosterone, including conditions such as primary testicular failure, Klinefelter syndrome, orchidectomy, and pituitary-hypothalamic injury. The drug is not approved for age-related testosterone decline in the absence of a clinical syndrome, a distinction the FDA reinforced in a 2015 drug safety communication.

The 2015 FDA communication also mandated updated labeling on cardiovascular risk across all testosterone products, a regulatory response to two observational studies that raised signals, later contested by the T-Trials data. Testosterone cypionate is a Schedule III controlled substance under DEA rules, meaning prescriptions may not be phoned in for refills and are subject to quantity limits at many pharmacies.

Generic testosterone cypionate (200 mg/mL in cottonseed oil, 10 mL multi-dose vials) is manufactured by multiple companies and listed in the FDA Orange Book as therapeutically equivalent to the original Depo-Testosterone brand.

The T-Trials: Core Evidence Base

The Testosterone Trials, known as the T-Trials, represent the largest and most rigorously designed placebo-controlled evaluation of testosterone treatment in older men to date. Published in the New England Journal of Medicine in 2016 (N=788), the T-Trials enrolled men aged 65 and older with confirmed total testosterone below 275 ng/dL and at least one age-related symptom. Participants received transdermal testosterone gel (target serum level 500 ng/dL) or placebo for 12 months across seven coordinated sub-trials.

The sexual function sub-trial showed a statistically significant improvement in the Psychosexual Daily Questionnaire sexual activity score: mean increase of 0.58 points on testosterone vs. 0.22 on placebo (P<0.001). The physical function sub-trial did not reach its primary walking-distance endpoint, but participants on testosterone walked a statistically significant 34 meters farther on the 6-minute walk test at 6 months. The vitality sub-trial showed modest but statistically significant improvement in fatigue scores on the FACIT-Fatigue scale (P=0.006).

Bone density data from the T-Trials, published separately in NEJM 2017, showed a 7.5% increase in volumetric trabecular bone density at the lumbar spine (P<0.001) and a 3.7% increase at the hip, with estimated bone strength also rising significantly. Coronary artery plaque volume increased by 41 mm³ in the testosterone group vs. 22 mm³ in the placebo group (P=0.002), though the clinical meaning of this finding is debated.

While the T-Trials used a transdermal gel formulation rather than testosterone cypionate specifically, the Endocrine Society guideline treats all testosterone preparations as pharmacologically equivalent for the purpose of evidence-based recommendations, a position consistent with pharmacokinetic data comparing ester formulations.

Dosing Protocols for Testosterone Cypionate

The standard starting dose for male hypogonadism is 100 to 200 mg intramuscularly (IM) every 7 to 14 days. Most clinicians begin at 100 to 150 mg weekly or 200 mg every two weeks and adjust based on mid-cycle trough or mid-point serum testosterone levels drawn 7 days after the most recent injection (for weekly dosing) or at day 7 of a 14-day cycle.

Subcutaneous (SC) administration has gained traction as an alternative. A 2015 study in the Journal of Urology (N=40) found that SC testosterone cypionate at doses of 50 to 100 mg weekly produced stable mid-week serum testosterone levels in the 400 to 700 ng/dL range with a lower injection-volume burden and no significant injection-site reactions. Many telehealth and men's health clinics now default to SC dosing for patient convenience.

Twice-weekly dosing (e.g., 50 to 75 mg every 3.5 days) is preferred by some prescribers because it reduces peak-to-trough variability. Testosterone cypionate has a half-life of approximately 8 days, so a single weekly injection produces a serum peak around day 2, 3 and a trough by day 7, a swing that some patients experience as symptom cycling.

The Endocrine Society guideline recommends targeting a mid-normal serum testosterone range of 400 to 700 ng/dL, avoiding supraphysiologic peaks above 1 to 000 ng/dL. Dose adjustments should be made no sooner than 6 to 8 weeks after starting or changing the regimen, allowing sufficient time for new steady-state levels.

HealthRX Dosing Decision Framework for Testosterone Cypionate

| Patient Profile | Starting Dose | Route | Monitoring Draw Timing | |---|---|---|---| | Age <50, symptomatic primary hypogonadism | 100 mg weekly | IM or SC | Day 7 (trough) | | Age <50, hypogonadotropic, fertility desired | Hold TRT; refer to reproductive endocrinology | N/A | Baseline LH, FSH, semen analysis | | Age 50, 65, confirmed low T, no polycythemia | 100 to 150 mg weekly or 200 mg Q2W | IM or SC | Day 7 (weekly) or Day 7 of cycle (Q2W) | | Age >65, T <275 ng/dL, symptomatic | 100 mg weekly, titrate cautiously | SC preferred | Day 7; Hct at 3 months | | Hematocrit >50% at baseline | Reduce dose or hold; address secondary causes | N/A | Repeat Hct in 6 weeks |

Monitoring Requirements and Safety Parameters

Monitoring is not optional. The Endocrine Society guideline specifies serum testosterone measurement at 6 to 8 weeks after initiation, then every 6 to 12 months once stable. Hematocrit must be checked at 3 months, then every 6 to 12 months. The guideline advises withholding testosterone if hematocrit exceeds 54%, resuming at a lower dose once the level normalizes.

Polycythemia is the most common dose-related adverse effect, occurring in approximately 3 to 18% of treated men depending on route and dose, per a 2017 systematic review in the Journal of Clinical Endocrinology and Metabolism. Subcutaneous injection and lower weekly doses appear to reduce this risk compared with high-dose IM every-2-week regimens.

Prostate monitoring follows the Endocrine Society schedule: PSA at baseline, 3 to 6 months, then annually for men over 40. Testosterone does not cause prostate cancer, but it can accelerate growth of pre-existing prostate cancer. Men with active or suspected prostate cancer are an absolute contraindication to testosterone therapy per FDA labeling.

Bone mineral density measurement by DEXA scan is recommended at baseline in men with osteoporosis risk, then repeated at 1 to 2 years. The T-Trials bone sub-trial showed measurable density gains in as little as 12 months, as published in NEJM 2017.

Lipid panels should be checked at baseline and at 6 to 12 months. Testosterone cypionate modestly lowers HDL cholesterol in some patients, an effect documented in a 2010 Cochrane review of testosterone replacement trials. Liver function tests are not routinely required with injectable testosterone, which bypasses first-pass hepatic metabolism, unlike oral methyltestosterone.

Sleep apnea screening is warranted before and after initiating therapy. Exogenous testosterone can worsen existing sleep-disordered breathing, and untreated obstructive sleep apnea independently suppresses testosterone, complicating clinical decisions in men with both conditions.

Cardiovascular Safety: What the Evidence Actually Shows

Cardiovascular risk from testosterone replacement therapy has been debated since 2010, when an NIH-funded trial (Basaria et al., NEJM 2010, N=209) was stopped early after a higher rate of adverse cardiovascular events in the testosterone arm. The study enrolled men with high cardiovascular risk at baseline, limiting generalizability.

The T-Trials coronary artery calcium and plaque data (published in NEJM 2017) showed increased non-calcified plaque volume in the testosterone group, raising concern without demonstrating a difference in clinical events. Coronary artery calcium scores did not differ between groups.

Conversely, a large 2023 FDA-mandated randomized trial, TRAVERSE (N=5,204, NEJM 2023), reported that testosterone replacement therapy in men with hypogonadism and high cardiovascular risk was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months. The TRAVERSE trial specifically evaluated men on TRT with pre-existing cardiovascular disease or high 10-year risk. The primary endpoint, a composite of cardiovascular death, non-fatal MI, and non-fatal stroke, occurred in 7.0% of testosterone-treated men vs. 7.3% on placebo (hazard ratio 0.96; 95% CI 0.78, 1.17). Non-inferiority was met.

Atrial fibrillation occurred more frequently in the testosterone group (3.5% vs. 2.4%, P=0.02), and acute kidney injury was also numerically higher. These findings led the FDA to update testosterone product labeling in 2024 to include atrial fibrillation as a potential risk.

Shared decision-making on cardiovascular risk should occur before prescribing, using the ACC/AHA 10-year ASCVD calculator. Men with recent MI, stroke, or unstable angina are generally not candidates for testosterone initiation until cardiovascular status is stable.

Fertility Preservation and Alternatives in Younger Men

Testosterone cypionate suppresses the hypothalamic-pituitary-gonadal axis through negative feedback, reducing gonadotropin secretion and halting spermatogenesis within 6 to 12 weeks in most men. Azoospermia or severe oligospermia is a predictable consequence of continuous TRT in men of reproductive age, a finding replicated across multiple controlled trials.

Men who desire future fertility should not start testosterone cypionate without a fertility consultation. Sperm banking before initiation is strongly recommended by the American Society for Reproductive Medicine. Recovery of spermatogenesis after stopping TRT can take 6 to 24 months and is not guaranteed, particularly after prolonged use.

Alternatives for hypogonadotropic hypogonadism in men who want to preserve fertility include human chorionic gonadotropin (hCG) monotherapy or in combination with follicle-stimulating hormone (FSH). A 2019 review in Fertility and Sterility found that hCG 1,500, 3 to 000 IU subcutaneously three times weekly raised intratesticular testosterone and maintained sperm production in most men with hypogonadotropic hypogonadism, supporting its use as a fertility-sparing option.

Clomiphene citrate (50 mg every other day to daily) is used off-label to stimulate endogenous testosterone by blocking estrogen receptors at the hypothalamus, increasing LH and FSH output. It is not FDA-approved for male hypogonadism, and long-term controlled trial data remain limited.

Managing Estradiol and Aromatization

Testosterone aromatizes to estradiol in adipose tissue. In men on testosterone cypionate, estradiol levels can rise into ranges associated with gynecomastia, water retention, and mood changes. The Endocrine Society guideline does not recommend routine aromatase inhibitor (AI) use in men on TRT, reserving AI therapy for men with symptomatic estradiol elevation (confirmed E2 above 50 pg/mL) plus clinical signs.

Anastrozole 0.5 to 1 mg twice weekly or exemestane 12.5 mg every other day are used off-label in this setting. Aggressive estradiol suppression causes its own problems, including reduced bone density, worsening lipid profiles, and sexual dysfunction. A 2013 trial by Finkelstein et al. in NEJM (N=198) elegantly demonstrated that estradiol, not testosterone alone, mediates fat accumulation and some sexual function in men, underscoring the importance of maintaining estradiol in the physiologic range rather than suppressing it to zero.

Men with higher body fat percentages aromatize more testosterone and may require dose adjustment or modest AI support more often than lean men.

Side Effects That Require Clinical Attention

Adverse effects from testosterone cypionate range from mild and manageable to potentially serious. The FDA prescribing label lists the following as the most clinically relevant:

Polycythemia. Hematocrit rises in 3 to 18% of men, increasing thrombosis risk. Phlebotomy or dose reduction is used to manage elevated hematocrit. Patients should avoid dehydration, which concentrates the blood further.

Injection site reactions. Pain, swelling, and induration occur more frequently with IM gluteal injections than with SC abdominal or thigh injections. Rotation of injection sites and using 25-gauge needles for SC administration reduces local reactions substantially.

Gynecomastia. Breast tissue enlargement results from elevated estradiol. Dose reduction or short-term tamoxifen 20 mg daily for 3 months may resolve mild to moderate cases, per a Cochrane review on gynecomastia treatment.

Testicular atrophy. Suppression of LH and FSH reduces intratesticular testosterone, shrinking testicular volume over months. Some men use adjunct hCG (500, 1 to 000 IU SC twice weekly) to maintain testicular size and preserve some residual Leydig cell function, though this is an off-label practice.

Sleep apnea exacerbation. Testosterone stimulates erythropoietin and may worsen upper airway muscle tone. Men with sleep apnea symptoms should undergo overnight oximetry or polysomnography before and 3 months after starting therapy.

Acne and oily skin. Androgenic stimulation of sebaceous glands affects roughly 10 to 15% of men on TRT. Topical retinoids or dose reduction typically resolves this.

Mood effects. Irritability and mood swings are more common when testosterone peaks are supraphysiologic. Twice-weekly dosing smooths out peaks and often resolves mood cycling reported with every-2-week IM injections.

The 2023 TRAVERSE trial added atrial fibrillation (3.5% TRT vs. 2.4% placebo) and pulmonary embolism (0.9% TRT vs. 0.5% placebo) to the list of signals requiring patient disclosure during informed consent.

Does Insurance Cover Testosterone Cypionate for Hypogonadism?

Generic testosterone cypionate is among the least expensive testosterone formulations available, with retail pricing around $30, $80 per 10 mL vial (200 mg/mL) at most US pharmacies. Most commercial insurance plans cover it for documented male hypogonadism with prior authorization based on two low morning testosterone values plus symptom documentation. Medicare Part D covers testosterone cypionate under most formularies when the diagnosis code Z31.61 (encounter for male factor infertility) or E29.1 (testicular hypofunction) is correctly applied.

Prior authorization requirements typically ask for two laboratory results below the plan's threshold (commonly 300 ng/dL), a diagnosis of primary or secondary hypogonadism, and documentation that the prescriber has reviewed cardiovascular and prostate risk. Denials usually occur when testing was performed at midday rather than in the morning, when a single draw (not two) was submitted, or when the diagnosis code reflects "age-related" rather than pathological hypogonadism.

GoodRx and similar discount programs bring the out-of-pocket cost below $35 per vial at many chains, making testosterone cypionate accessible even without insurance coverage. Compounding pharmacies fill testosterone cypionate in concentrations not available commercially (e.g., 100 mg/mL for lower-volume SC dosing), but compounded preparations fall outside FDA oversight and quality standards.

How Long Before Testosterone Cypionate Works?

The timeline of benefit varies by symptom domain, and patients should be told this explicitly before starting. Data from the T-Trials and supporting pharmacokinetic literature outline the following approximate windows:

Libido and sexual desire respond earliest, often within 3 to 6 weeks of reaching therapeutic serum levels. Erectile function improvement typically lags by 3 to 6 months, and some men do not respond without addressing concurrent causes such as vascular disease or medication-induced dysfunction.

Mood and energy improvements are reported at 3 to 6 weeks by many patients, though the T-Trials vitality sub-trial required 12 months of treatment to demonstrate statistically significant differences on the FACIT-Fatigue scale (P=0.006), suggesting that subjective early improvements may partly reflect expectancy effects.

Lean body mass gains are detectable by DEXA at 3 months and become clinically meaningful at 6 to 12 months, with a 2001 NEJM testosterone dose-response trial (N=61) showing a dose-dependent increase in fat-free mass of 3.2 kg at the 600 mg weekly dose and 1.9 kg at 300 mg weekly over 20 weeks.

Bone mineral density changes are slowest. The T-Trials bone sub-trial measured significant gains only after 12 months. Treatment duration of at least 2 years is generally needed to see clinically meaningful skeletal benefit.

If serum testosterone is confirmed to be in the target range (400 to 700 ng/dL) and the patient reports no benefit after 6 months, it is worth reassessing the original diagnosis, checking for concurrent conditions (depression, sleep apnea, medication side effects), and confirming SHBG and free testosterone, because high SHBG can mask low free testosterone even when total T appears adequate.

The Endocrine Society guideline states: "We recommend treating men who have both consistently low serum testosterone concentrations and symptoms or signs of androgen deficiency with testosterone therapy to induce and maintain secondary sexual characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density."